Danja Monje
Bayer (Germany)(DE)
Publications by Year
Research Areas
Venous Thromboembolism Diagnosis and Management, Atrial Fibrillation Management and Outcomes, Blood Coagulation and Thrombosis Mechanisms, Cardiac Arrhythmias and Treatments, Coronary Interventions and Diagnostics
Most-Cited Works
- → Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study(2015)244 cited
- → Patient Management Strategies and Long-Term Outcomes in Isolated Distal Deep-Vein Thrombosis versus Proximal Deep-Vein Thrombosis: Findings from XALIA(2019)29 cited
- → Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE(2017)23 cited
- → Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both(2020)21 cited
- → XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America(2019)19 cited
- → Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA‐LEA noninterventional studies(2021)18 cited
- → Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study(2017)10 cited
- → Patient-Reported Treatment Experience with Oral Rivaroxaban: Results from the Noninterventional XALIA Study of Deep-Vein Thrombosis(2018)5 cited
- → Xalia, a Non-Interventional Study Comparing Rivaroxaban with Standard Anticoagulation for Initial and Long-Term Therapy in Deep Vein Thrombosis(2015)3 cited
- → A Pooled Analysis of the Xalia and Xalia-Lea Non-Interventional Studies of Rivaroxaban Versus Standard Anticoagulation in Venous Thromboembolism(2017)3 cited